HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NSCH becomes Proteonomix

This article was originally published in The Rose Sheet

Executive Summary

Biotech firm National Stem Cell Holdings announces name change to Proteonomix and change of trading symbol from NHGI to PROTD, makes official its focus on proteomics and its movement from strict R&D to commercial product development. In July, the company introduced its new cosmeceutical line featuring "unique natural matrix of proteins called Secreted Matrix and Matrix NC-138" through subsidiary Proteoderm, whose first public display of the skin-care products at recent International Anti-Aging Conference in Washington D.C. met with an "encouraging response." Proteoderm has plans for "an extensive array of specialty skin-care products" formulated with its proprietary proteins derived from non-embryonic stem cells," according to the release. Protenomix believes it now is in a position to raise capital in "very challenging financial environment for product commercialization.

You may also be interested in...

“Stem-cell-derived” skin care

Proteonomix's line of "stem-cell-derived" anti-aging cosmetics will debut in first quarter of 2009, biotech firm announces Oct. 8. The serum, day cream, night cream, cleanser and exfoliator rely on a proprietary matrix of proteins called Matrix NC-138 - derived from culture medium of non-embryonic, human stem cell derivatives - to stimulate collagen production, which leads to a reduction of wrinkles, company says. Subsidiary Proteoderm's anti-aging solutions "can bring patients higher satisfaction and results, working to revitalize and rejuvenate cells to help drastically reverse the effects of aging," according to the release. Line will be distributed through physicians' offices. Firm changed its name from National Stem Cell Holdings to Proteonomix in September (1"The Rose Sheet" Sept. 1, 2008, In Brief)

Strides Targets $200-400m From Generic Injectables In Mid-Term

Strides has set a sales target of $200-400m for Stelis’s generic injectables business in two to four years as part of its plan to reach $800m in total revenues in four years. Meanwhile, Stelis’s Rh-teriparatide for osteoporosis and sodium hyaluronate for osteoarthritis await Phase III incremental studies in the US.

Abbott Readying Vildagliptin ER In India Amid Price Competition

Abbott is developing an extended release version of vildagliptin in India, adding a new dimension to the market dynamics for the DPP-4 inhibitor, which has seen a key patent expire. Sustained release vildagliptin products from Wockhardt and Synokem also appear to be in the works.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts